OnabotulinumtoxinA for Spasticity in Multiple Sclerosis

Medical Necessity Assessment

A 42-year-old female patient with severe spasticity secondary to spinal cord lesions related to an underlying autoimmune neurological condition, such as multiple sclerosis, may benefit from onabotulinumtoxinA treatment, as documented by the American Academy of Family Medicine 1, 2
The American Academy of Neurology guidelines recommend onabotulinumtoxinA for spasticity involving the lower limbs that warrants treatment, with a focus on patients with severe spasticity secondary to multiple sclerosis 2, 4
Patients with documented functional impairment, such as difficulty walking, may benefit from onabotulinumtoxinA treatment, as supported by the American Academy of Family Medicine 1, 2

OnabotulinumtoxinA is safe and effective for the treatment of lower limb spasticity in adults, including those with multiple sclerosis, and should be offered as a treatment option, according to the American Academy of Family Medicine 1, 2, 3
The 2025 VA/DoD Clinical Practice Guidelines support the use of botulinum toxin for patients with focal spasticity, including those with multiple sclerosis, with a focus on improving passive function and reducing muscle tone 5, 6
Botulinum toxin has been shown to reduce muscle tone and improve passive function, such as improved range of motion, in patients with lower limb spasticity secondary to multiple sclerosis, as documented by the American Academy of Family Medicine 1, 2

The current treatment plan targets the appropriate muscles for the patient's specific pattern of spasticity, including the right gastrocnemius, soleus, tibialis posterior, rectus femoris, and vastus intermedius, with dosing supported by the Annals of Internal Medicine 5, 6
The total dose of 375 units falls within the FDA-approved range for adult lower limb spasticity, as supported by the Annals of Internal Medicine 5, 6

While botulinum toxin can improve passive function, evidence for improvement in active function is less robust, highlighting the need for comprehensive rehabilitation programs, including physical therapy, as supported by the American Academy of Family Medicine 1, 2
Oral antispasmodics like baclofen may be less effective for focal ankle spasticity compared to botulinum toxin, according to the Annals of Internal Medicine 5, 6